MedPath

A community-based study of prevalence of skin disorders in semi-urban and urban Telangana State

Completed
Conditions
Skin disorder being screened
Registration Number
CTRI/2022/12/048189
Lead Sponsor
Pfizer Inc
Brief Summary

Skin diseases contributed about 2% of the global burden of diseases measured in Disease Adjusted Life Years (DALYs) (1). The prevention and management of skin diseases received less attention in the past decades due to low mortality rates. However, a recent Global Burden of Disease Study finding revealed that skin diseases rank 18 in top 20 diseases in terms of DALYs and is fourth leading cause of nonfatal disease burden (2). Further, skin diseases increase clinical depression and anxiety. The prevalence and pattern of skin diseases are influenced by the overall ecosystem of the region including sociocultural milieu, topography, nutrition, genetics etc.

In India, skin diseases have been profiled through hospital-based studies with low levels of prevalence (3-7) as compared to community-level. The prevalence varied from 4.2% to 11.6% in the general population. However, high prevalence has been reported (30%–40%) in pediatric population (8, 9) and 60% in a community-based survey in the central India (10). There is a dearth of data about prevalence in skin diseases among semi-urban/rural communities in Telangana.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • 1.Subjects age 2 years and above 2.Subjects who have skin disorders 3.Able to provide informed consent/ assent (in case of children).
  • 4.Subjects who reside in the study area (for at least 6 months).
Exclusion Criteria
  • 1.Subjects with no skin disorders.
  • 2.Subjects below the age of 2 years 3.Subjects unable to participate in study related procedures 4.Subjects unwilling or unable to provide informed consent/assent 5.Subjects who do not reside in the area (at 6 months) and/or are unlikely to reside in the area until end of December 2023.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
we aim to determine the prevalence of skin disorders in urban and semi urban communities and their impact on quality of life.12 to 13 months
Secondary Outcome Measures
NameTimeMethod
•To determine impact on quality of life due to skin disorders•To explore influence of predisposing conditions including influence of geography on skin disorders and quality of life

Trial Locations

Locations (1)

SHARE INDIA

🇮🇳

Medchal, TELANGANA, India

SHARE INDIA
🇮🇳Medchal, TELANGANA, India
Dr Manjunath Dinaker
Principal investigator
9849886824
mdinaker2511@gmail.com
Dr Vijay Yeldandi
Principal investigator
9849886824
vijayyeldanadi@shareindia.org

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.